![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Founded
Address
Celleration Inc
6321 Bury Drive
Suite 15
Eden Prairie, MN 55346
United States
Celleration Inc
6321 Bury Drive
Suite 15
Eden Prairie, MN 55346
United States
Website
KANDO id: 39255
Corporate information
Official name
Celleration Incorporated
Registration country
Official identities
US CIK 0001296585
Company type
Medical device company focused on developing and commercializing therapeutic ultrasound productsFunding rounds
Series E
( )
| Investor | Profile | Country | |
|---|---|---|---|
|
AAVIN Equity Advisors LLC | ||
|
Baird Venture Partners | ||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
CID Capital | ||
|
New Science Ventures (NSV) | Venture capital firm investing in both early and late stage companies using novel scientific approaches to address significant unmet needs. | |
|
|
Seneca Health Partners | ||
|
Triathlon Medical Ventures LLC | ||
|
|
Upper Lake Growth Capital | Early stage biomedical venture capital firm, with a focus on the US Midwest |
Series D
( )
| Investor | Profile | Country | |
|---|---|---|---|
|
Affinity Capital Management | ||
|
|
New Science Ventures (NSV) | Venture capital firm investing in both early and late stage companies using novel scientific approaches to address significant unmet needs. | |
|
|
Prism Opportunity Fund | ||
|
|
Seneca Health Partners |
Series D
( )
| Investor | Profile | Country | |
|---|---|---|---|
|
|
Upper Lake Growth Capital | Early stage biomedical venture capital firm, with a focus on the US Midwest |
Series C
( )
| Investor | Profile | Country | |
|---|---|---|---|
|
|
Triathlon Medical Ventures LLC | ||
|
|
Upper Lake Growth Capital | Early stage biomedical venture capital firm, with a focus on the US Midwest |
Series C
( )
| Investor | Profile | Country | |
|---|---|---|---|
|
|
New Science Ventures (NSV) | Venture capital firm investing in both early and late stage companies using novel scientific approaches to address significant unmet needs. |
Investment activity status
Active investor